Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06575699
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-22
Brief Title:
Rectus Sheath Block for Analgesia After Gynecological Laparotomy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Rectus Sheath Block With Liposomal Bupivacaine for Postoperative Analgesia Following Gynecologic Oncology Surgery A Pilot Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Thirty subjects undergoing laparotomy for Gynecologic oncology surgery will be prospectively enrolled and will receive a bilateral rectus sheath block RSB under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 025 per side Cases will be matched in a 12 ratio by age race insurance status and duration of surgery with historical controls who received postoperative analgesia using thoracic epidural analgesia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None